Fulcrum Therapeutics, Inc. (FULC)

Market Cap	282.30M -44.1%
Revenue (ttm)	n/a
Net Income	-85.00M
EPS	-1.21
Shares Out	76.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	447,172
Open	3.700
Previous Close	3.690
Day's Range	3.680 - 3.725
52-Week Range	2.830 - 15.740
Beta	2.63
Analysts	Hold
Price Target	3.67 (-0.81%)
Est. Earnings	Oct 28, 2026

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 9
• Stock Exchange: Nasdaq
• Ticker Symbol: FULC
• Website: https://www.fulcrumtx.com

Analyst Summary

According to 5 analysts, the average rating for FULC stock is "Hold." The 12-month stock price target is $3.67, which is a decrease of -0.81% from the latest price.

Price Target

$3.67

(-0.81% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 5, 2026

Data Sources Report a data error